Marinobufagenin
Appearance
(Redirected from Marinobufagin)
![]() | |
Names | |
---|---|
IUPAC name
3β,5-Dihydroxy-14,15-epoxy-5β,14β-bufa-20,22-dienolide
| |
Systematic IUPAC name
5-[(1R,2aR,3aS,3bR,5aS,7S,9aR,9bS,11aR)-5b,7-Dihydroxy-9a,11a-dimethylhexadecahydronaphtho[1′,2′:6,7]indeno[1,7a-b]oxiren-1-yl]-2H-pyran-2-one | |
Other names
Marinobufagin, Marinobufagenin
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C24H32O5 | |
Molar mass | 400.515 g·mol−1 |
Hazards | |
Occupational safety and health (OHS/OSH): | |
Main hazards
|
Toxic |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Marinobufagenin (marinobufagin) is a cardiotonic bufadienolide steroid. It can be found in the plasma and urine of human subjects with myocardial infarction, kidney failure, and heart failure.[1] It is also secreted by the toad Bufo rubescens[2] and other related species such as Bufo marinus. It is a vasoconstrictor with effects similar to digitalis.[3]
References
[edit]- ^ Tian, Jiang (7 September 2010). "Renal ischemia regulates marinobufagenin release in humans". Hypertension. 56 (5): 914–919. doi:10.1161/hypertensionaha.110.155564. PMC 2959137. PMID 20823380.
- ^ Cunha Filho, GA; Schwartz, CA; Resck, IS; Murta, MM; Lemos, SS; Castro, MS; Kyaw, C; Pires Jr, OR; et al. (2005). "Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens". Toxicon. 45 (6): 777–82. doi:10.1016/j.toxicon.2005.01.017. PMID 15804527.
- ^ Fedorova, OV; Talan, MI; Agalakova, NI; Lakatta, EG; Bagrov, AY (2002). "Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension". Circulation. 105 (9): 1122–7. doi:10.1161/hc0902.104710. PMID 11877366.